medigraphic.com
Colegio de Medicina Interna de México.

2007, Number 5

<< Back Next >>

Med Int Mex 2007; 23 (5)

Bezafibrate mixed with simbastatine or ezatimibe effects over endothelial function and its lipid profile in hypersensitive patients with hypertrigliceridemia, hypoalphalipopteinemia, and limit LDL-cholesterol

García JE, Carranza MJ, Álvarez AC, Jaubert MJ, Campos PY

Language: Spanish
References: 26
Page: 371-375
PDF size: 178.02 Kb.


ABSTRACT

Background: The disorders of lipoproteins metabolism (dyslipidemias) constitute factors of high risk for coronary heart disease. This makes necessary to look for antihypertensive and lipid-lowering treatments that improve the endothelial function.
Objetive: To determine if the effects of the fibrates in combination with statin and with ezetimibe on lipid profile are associated to improvement of the endothelial function in hypertensive patients with high triglyceride and low HDL-cholesterol levels.
Patients and Method: Twelve patients were included in a clinical, active treatments controlled: bezafibrato+ezetimibe (BEZA+EZE) and bezafibrato+simvastatina (BEZA+SIMVA), in a cross over model, with duration of 4 weeks. Muscular and hepatic enzymes, and ultrasonographic evaluation of the endothelial function were measured.
Results: Both treatments reduced the levels of total cholesterol and triglycerides significantly, and they increased those of the HDL cholesterol; while only BEZA+SIMVA reduced those of the cholesterol LDL. On the endothelial function only BEZA+EZE produced a significant improvement. This treatment also reduced the diastolic blood pressure. There were not changes in the hepatic neither muscular enzymes with none of the treatments.
Conclusions: The combination of bezafibrate and ezetimibe is innocuous and effective for the patients with metabolic syndrome and bordering cholesterol LDL; in addition it shows greater benefits than the combination of bezafibrate and simvastatina, since it improves the endotelial vasomotor function.


REFERENCES

  1. Durrington P. Dyslipidaemia. Lancet 2003;362:717-31.

  2. Velázquez-Monroy O, Rosas-Peralta M, Lara-Esqueda A, Pastelín-Hernández G, Grupo ENSA 2000. Prevalencia e interrelación de enfermedades crónicas no transmisibles y factores de riesgo cardiovascular en México. Arch Cardiol Mex 2003;72:62-77.

  3. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Valles V, et al. High prevalence of metabolic syndrome in México. Arch Med Res 2004;35:76-81.

  4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circulation 2002;106:3143.

  5. Sever P, Dahlof B, Poulter N, Wedel H, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized trial. Lancet 2003;361:1149-58.

  6. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356-63.

  7. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005;111:363-8.

  8. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, et al. Guidelines for ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol 2002;39:257-65.

  9. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease. Lancet 1994;344:383-1388.

  10. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.

  11. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.

  12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatina in 20,536 high-risk individuals. Lancet 2002;360:7-22.

  13. Rubins RH, Robins SJ, Collins D, Fye CL, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.

  14. The Bezafibrate Infarction Prevention (BIP) Study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000;102:21-27.

  15. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.

  16. Diamant M, Tushuizen ME. The metabolic syndrome and endothelial dysfunction: ccommon highway to type 2 diabetes and CVD. Curr Diab Rep 2006;6:279-86.

  17. Dogra GK, Watts GF, Chan DC, Stanton K. Statin therapy improves brachial artery vasodilator function in patient with Type 1 diabetes and microalbuminuria. Diabet Med 2005;22:239-42.

  18. Strey CH, Young JM, Molyneux SL, George PM, et al. Endothelium- ameliorating efftcs o statin therapy and coenzyme Q 10 reductions in chronic heart failure. Atherosclerosis 2005;179:201-6.

  19. Guerra ER, Shirwany A, Gaschen J, Jolly S, et al. Effect of Gemfibrozil on brachial artery vascular reactivity in men with reduced HDL cholesterol. JACC 2001;37SA:1A-648A.

  20. Capell W, DeSouza C, Poirieir P, Bell M, et al. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridaemia. Arterioscler Thromb Vasc Biol 2003;23:307-13.

  21. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, et al. Simvastatin versus Ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356-63.

  22. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, Lothar R, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for “pleitropic” functions of statin therapy. Eur Heart J 2006;27:1182-90.

  23. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003;107:1733-7.

  24. Van Venrooij FV, van de Ree MA, Bots ML, Stolk RP, et al. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2002;25:1211-6.

  25. Beishuizen ED, Tamsma JT, van de Ree MA, van der Vijver JC, et al. The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2005;28:1668-74.

  26. Lekakis JP, Papamichael CM, Barbaki P, et al. Endothelial dysfunction is frequently present in hyperlipidaemic patients despite adequate reduction of LDL-cholesterol. Eur Heart J 2001;22S:651.




2020     |     www.medigraphic.com